Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most common
neurodegenerative disorders encountered in clinical practice. Whilst dementia has long …

Alzheimer's disease (AD) and other dementias represent a significant and increasing clinical
challenge. This review highlights current treatment options for AD and the main focusses of …

The prevalence of Parkinson's disease (PD) increases with age and is projected to increase
in parallel to the rising average age of the population. The disease can have significant …

The core symptoms of different dementia subtypes are the behavioral and psychological
symptoms of dementia (BPSD) and its neuropsychiatric symptoms (NPS). BPSD symptoms …

Dementia affects about 47 million people worldwide, number expected to exponentially
increase within 30 years. Alzheimer's disease (AD) is the most common dementia type …

According to the World Alzheimer's report, dementia was estimated to affect 50 million
worldwide in 2018, number expected to increase to more than 150 million within 30 years …

The British Association for Psychopharmacology (BAP) coordinated a meeting of experts to
review and revise its first (2006) Guidelines for clinical practice with anti-dementia drugs. As …

Abstract Introduction: Nonpharmacological therapies (NPTs) can improve the quality of life
(QoL) of people with Alzheimer's disease (AD) and their carers. The objective of this study …

Objectives: Behavioral and psychological symptoms of dementia (BPSD) are nearly
universal in dementia, a condition occurring in more than 40 million people worldwide …

Alzheimer's disease (AD) is the most common cause of dementia worldwide. The etiology is
multifactorial, and pathophysiology of the disease is complex. Data indicate an exponential …